Product Details
| Product Name:
Roniciclib |
CAS No.:
1223498-69-8 |
| Purity:
98.63% |
Supply Ability:
10g |
| Release date:
2025/11/10 |
Product Introduction
Bioactivity
| Name | Roniciclib |
| Description | Roniciclib (BAY 1000394) is a potent pan-CDK inhibitor and a novel oral cytotoxic agent. Roniciclib inhibits the activity of cell-cycle CDKs CDK1, CDK2, CDK3, CDK4, and of transcriptional CDKs CDK7 and CDK9 with IC(50) values in the range between 5 and 25 nmol/L. |
| In vitro | Roniciclib inhibits the kinase activity of the cell-cycle CDKs CDK1/cyclin B, CDK2/cyclin E, and CDK4/cyclinD (IC50: 7, 9, and 11 nM, respectively). Roniciclibeffectively inhibits the proliferation of various human and murine tumor cell lines with a very balanced profile (mean IC50 on human tumor cells: 16 nM). The transcriptional CDKs CDK9/cyclin T1 and CDK7/cyclin H/MAT1 are inhibited in a similar range (5 and 25 nM) [1][2]. |
| In vivo | Roniciclib has low blood clearance rates in mouse, rat, and dog (0.51, 0.78, and 0.50 Lh-1kg-1, respectively). Roniciclib strongly inhibits the growth of HeLa-MaTu tumors that have been grown to a size of approximately 50mm2 before the start of treatment. Roniciclib (1.5 and 1 mg/kg) treatment slow tumor growth to T/C values of 0.15 and 0.62, respectively. The addition of Roniciclib to cisplatin causes a strong tumor growth inhibition with T/C values of 0.01 (1.0 mg/kg Roniciclib) and -0.02 (1.5 mg/kg Roniciclib) [1][2]. |
| Storage | store at low temperature,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 249 mg/mL (578.48 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (11.62 mM), Sonication is recommended.
|
| Keywords | Roniciclib | Inhibitor | inhibit | Cyclin dependent kinase | CDK9/cyclinT1 | CDK9/cyclin T1 | CDK7/Cyclin H/MAT1 | CDK4/CyclinD | CDK4/cyclin D | CDK3/cyclinE | CDK2/cyclinE | CDK1/CyclinB | Cdk1/cyclin B | CDK | BAY-1000394 | BAY1000394 |
| Inhibitors Related | Ribociclib | Ro-3306 | Abemaciclib | Rafoxanide | AT7519 | Palbociclib monohydrochloride | CASIN | Palbociclib | GW 441756 | Sodium Oxamate | Dinaciclib | Abemaciclib methanesulfonate |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Orally Active Compound Library | Bioactive Compounds Library Max | Cell Cycle Compound Library | Fluorochemical Library | Anti-Cancer Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:148556-27-8
$195.00 / 5mg
-
CAS:179068-02-1
$35.00 / 2mg
-
CAS:2291360-73-9
$97.00 / 1mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States